NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Champions Oncology, Inc. (CSBR) Stock Analysis

Champions Oncology, Inc. (CSBR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CSBR

$5.22

−$0.06 (−1.14%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CSBR with… →

CSBR Key Statistics

As of Sep 4, 2026
Trading
Open
$5.28
Previous Close
$5.28
Day's Range
5.06–5.41
52-Week Range
4.83–8.74
Volume
10.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.40
Valuation
Market Cap
$72.52M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
52.20
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.22
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.08
Financials (FY)
Revenue (FY)
$59.43M+4.36%
Net Income (FY)
−$1.18M−124.99%
Profit marginThe share of revenue left as profit after all costs and taxes.
−1.98%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.89M
1-Year Return
−24.57%
Dividend and dates
Earnings Date
September 10, 2026
Avg Volume
8.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CSBR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.46%
2025−19.37%
2024+52.49%
2023+24.61%
2022−46.05%
2021−22.52%
2020+29.53%
2019+6.66%
2018+101.29%
2017+53.36%
2016 (partial year)+27.14%

As of September 4, 2026.

CSBR Revenue and Earnings by Fiscal Year

FY ends April
Fiscal yearRevenueNet incomeNet margin
2025$59.43M−$1.18M−2.0%
2024$56.94M$4.70M8.3%
2023$50.16M−$7.28M−14.5%
2022$53.87M−$5.34M−9.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$59.43M$28.53M−$1.03M−$1.18M−2.0%
2024$56.94M$28.56M$4.85M$4.70M8.3%
2023$50.16M$20.75M−$6.92M−$7.28M−14.5%
2022$53.87M$24.34M−$4.45M−$5.34M−9.9%

Annual figures as reported, in the company's reporting currency. As of April 30, 2026.

CSBR Valuation vs Biotechnology Median

Median of 656 stocks
MetricCSBRBiotechnology medianvs median
P/S ratio1.2215.260.1x the median
Profit margin−1.98%0.00%2.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Champions Oncology, Inc. (CSBR) carries a market capitalisation of $72.52M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 214.

Over the past 52 weeks the price has ranged from $4.83 to $8.74. CSBR last closed at $5.22 on September 4, 2026. That is −$0.06 (−1.14%) against the previous close. The latest close sits 8.07% above that 52-week low.

Financial Health

In fiscal 2025, Champions Oncology, Inc. reported revenue of $59.43M. That is +4.36% against the prior fiscal year, when revenue was $56.94M. The same year closed with a net loss of $1.18M. The reported profit margin is −1.98%. That is 2 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.08.

Across the 4 fiscal years on file, revenue moves from $53.87M in 2022 to $59.43M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 52.2. Measured against sales, the shares trade at 1.22 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −24.57%. Across 10 years the annualized return works out at +12.91%. The reported beta is 0.4. Daily returns over the trailing 10 years annualize to a volatility of 68.24%.

Growth & Income

No dividend is on file for CSBR.

So far in 2026 the price is −24.46%. Across the complete calendar years on file, 2018 returned +101.29% and 2022 returned −46.05%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Champions Oncology, Inc. (CSBR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Champions Oncology, Inc. CSBR $72.52M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Champions Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Champions Oncology, Inc.

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Visit website →